{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-071078","form_type":"8-K","ticker":"REPL","cik":"0001737953","company_name":"Replimune Group, Inc.","filed_at":"2024-06-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.825323+00:00","generated_at":"2026-06-01T04:38:42.233066+00:00","sec_items":["1.01","3.02","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Replimune raises $100M in PIPE to fund RP1 commercialization; BLA filing on track for 2H 2024","bullets":["Issued 5.67M shares at $8.82/share and 5.67M pre-funded warrants at $8.819/warrant.","Gross proceeds ~$100M; expected closing June 14, 2024.","Proceeds to fully scale up for RP1 commercial launch in skin cancers, potential path to profitability.","Led by life-sciences institutional investor; Redmile, RTW, Boxer Capital participated.","RP1 IGNYTE trial in anti-PD1 failed melanoma showed strong data; BLA submission expected 2H 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-071078","json":"https://secwatch.observer/filing/0001104659-24-071078.json","markdown":"https://secwatch.observer/filing/0001104659-24-071078.md","text":"https://secwatch.observer/filing/0001104659-24-071078.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1737953/000110465924071078/0001104659-24-071078-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1737953/000110465924071078/tm2417173d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T04:38:42.233066+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}